| Cat.No. | Name | Information |
|---|---|---|
| M9872 | BS3 (bis(sulfosuccinimidyl)suberate) | BS3 (bis(sulfosuccinimidyl)suberate) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| M55737 | DM4-SMCC | DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker. |
| M55736 | Lys-SMCC-DM1 | Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. |
| M55735 | Doxorubicin-SMCC | Doxorubicin-SMCC is a agent-linker conjugate for ADC. |
| M55734 | Mal-PEG4-VC-PAB-DMEA-PNU-159682 | Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. |
| M55733 | Mal-amido-PEG8-Val-Ala-PAB-SG3200 | Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a conjugate for antibody-drug conjugate (ADC). |
| M49829 | SC-VC-PAB-MMAE | SC-VC-PAB-MMAE is part of a drug-linker conjugate for ADC (ADC) with anticancer activity, which consists of MMAE (a tubulin inhibitor) linked to a cleavable SC-VC-PAB linker. |
| M49827 | DBCO-(PEG)3-VC-PAB-MMAE | DBCO-(PEG)3-vc-PAB-MMAE is an active molecule coupler (drug-linker conjugate for ADC) consisting of auristatin E attached to a DBCO-(PEG)3-vc-PAB connector. It can be used for cancer research. In addition, DBCO-(PEG)3-vc-PAB-MMAE is a click chemistry that contains a DBCO moiety and can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing an Azide moiety. |
| M41010 | PB038 | PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan. |
| M41009 | Val-Ala-PAB-MMAE | Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. |
| M41008 | Val-Ala-PABC-Exatecan | Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor). |
| M40940 | Pinatuzumab vedotin | Pinatuzumab vedotin is an antibody-drug coupling (ADC) targeting CD22 containing the microtubule inhibitor monomethylauristatin E (MMAE) for studies related to diffuse large B-cell lymphoma. |
| M28881 | Mc-VC-PAB-SN38 | Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). |
| M28641 | Tesirine | Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity. |
| M28498 | Sulfo-PDBA-DM4 | Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. |
| M28205 | SGD-1910 | SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala. |
| M28111 | Lys-Nε-SPDB-DM4 | Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC). |
| M28031 | Mipsagargin | Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin. Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research. |
| M25312 | Zilovertamab vedotin | Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer. |
| M25258 | Cantuzumab ravtansine | Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody huC242 covalently linked via a disulfide bond to DM4. Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. |
| M25224 | Cantuzumab mertansine | Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
